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A deficiency in cystic fibrosis transmembrane conductance regulator (CFTR) function in 
CF leads to chronic lung disease. CF is associated with abnormalities in fatty acids, 
ceramides, and cholesterol, their relationship with CF lung pathology is not completely 
understood. Therefore, we examined the impact of CFTR deficiency on lipid metabolism 
and pro-inflammatory signaling in airway epithelium using mass spectrometric, protein 
array. We observed a striking imbalance in fatty acid and ceramide metabolism, associated 
with chronic oxidative stress under basal conditions in CF mouse lung and well-
differentiated bronchial epithelial cell cultures of CFTR knock out pig and CF patients. 
Cell-autonomous features of all three CF models included high ratios of ω-6- to 
ω-3-polyunsaturated fatty acids and of long- to very long-chain ceramide species (LCC/
VLCC), reduced levels of total ceramides and ceramide precursors. In addition to the 
retinoic acid analog fenretinide, the anti-oxidants glutathione (GSH) and deferoxamine 
partially corrected the lipid profile indicating that oxidative stress may promote the lipid 
abnormalities. CFTR-targeted modulators reduced the lipid imbalance and oxidative 
stress, confirming the CFTR dependence of lipid ratios. However, despite functional 
correction of CF cells up to 60% of non-CF in Ussing chamber experiments, a 72-h triple 
compound treatment (elexacaftor/tezacaftor/ivacaftor surrogate) did not completely 
normalize lipid imbalance or oxidative stress. Protein array analysis revealed differential 
expression and shedding of cytokines and growth factors from CF epithelial cells compared 
to non-CF cells, consistent with sterile inflammation and tissue remodeling under basal 
conditions, including enhanced secretion of the neutrophil activator CXCL5, and the T-cell 
activator CCL17. However, treatment with antioxidants or CFTR modulators that mimic 
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INTRODUCTION
Abnormal lipid levels in blood and lungs are a hallmark of 
cystic fibrosis (CF). Previous studies of CF children have 
demonstrated abnormal levels of polyunsaturated fatty acids 
(PUFA), sphingolipids, and several lipid markers of oxidative 
stress, and these defects correlate with CF inflammatory lung 
disease and tissue remodeling in patients (Scholte et al., 2019; 
Horati et  al., 2020) and in animal models (Freedman et  al., 
1999; Guilbault et al., 2009; Veltman et al., 2016). In particular, 
these studies revealed higher levels of the oxidative stress 
markers methionine sulfoxide (Chandler et  al., 2018), 
isoprostanes, and lysolipids (Scholte et  al., 2019; Horati et  al., 
2020) in broncho-alveolar lavage fluid (BALF) from human 
CF infants compared to non-CF infants, despite comparable 
inflammation and a lack of detectable bacterial infection. 
Furthermore, we  reported an increased ratio of long-chain 
to very long-chain ceramide species (LCC/VLCC; Scholte 
et al., 2019), confirming results with plasma from CF patients 
and in lung tissue and plasma from CF transmembrane 
conductance regulator (CFTR) knockout mice (Garic et  al., 
2017). Moreover, the increase in LCC/VLCC ratio in BALF 
from CF infants was positively correlated with chest computed 
tomography (CT) scores and multiple pro-inflammatory markers 
(Scholte et al., 2019; Horati et al., 2020) and altered recruitment, 
differentiation, and activity of neutrophils in the BALF of 
CF infants (Margaroli et al., 2019). Using the Cftrtm1eur F508del 
CFTR mouse model, in the absence of bacterial infection, 
we observed abnormal sphingosine phosphate (S1P) metabolism 
that correlated with enhanced lung macrophage and neutrophil 
infiltration, abnormal polarization of dendritic cells, increased 
mucus production, and enhanced responses to Lipo-saccharide 
(LPS) challenge, which could be  partially corrected with a 
S1P lyase inhibitor (Veltman et al., 2016). The extent to which 
changes in lipid metabolism contribute to inflammation and 
tissue remodeling in CF lung disease remains to be established. 
Hyperinflammation in CF lungs has been extensively studied 
(Murphy and Ribeiro, 2019). In F508del CFTR mice abnormal 
basal lipid metabolism coincides with enhanced responses to 
the pro-inflammatory and pro-fibrotic triggers LPS (Merkert 
et al., 2019), bleomycin (Huaux et al., 2013), and Pseudomonas 
infection (Palomo et  al., 2014). Whereas lysolipids and S1P 
are known to activate receptors and influence lung pathology, 
a change in lipid content, in particular, ceramide species and 
PUFA ω6–ω3 ratio is more likely to affect membrane 
microdomains, membrane trafficking, and the activity of 
membrane-associated transport and receptor systems that 
control basal and induced inflammation and tissue repair. In 
support of this, arachidonic acid/docosahexaenoic acid (AA/
DHA) imbalance has been associated with chronic lung disease 
in CF, COPD, and asthma (Kanagaratham et  al., 2014; Morin 
et  al., 2018; Fussbroich et  al., 2019; Teopompi et  al., 2019).
However, the molecular mechanisms by which CFTR 
deficiency leads to oxidative stress, skewed bioactive lipid 
metabolism, and pro-inflammatory signaling have not been 
resolved. Moreover, the effects of available and recently approved 
drugs that correct the trafficking of variant CFTR channels, 
including lumacaftor (VX-809), tezacaftor (VX-661), and 
elexacaftor (VX-445), or potentiate their channel gating activity 
(ivacaftor, VX-770), on bioactive lipid metabolism and 
downstream inflammatory signaling of CF airway epithelia 
have not been fully investigated. Recent studies show that 
the reduced pro-inflammatory signaling in isolated monocytes 
from patients with the channel gating variant R117H CFTR 
is enhanced after treatment with the potentiator Ivacaftor 
(VX-770; Hisert et  al., 2020). In contrast, inflammatory 
signaling was reduced in monocytes and plasma from patients 
homozygous for the F508del CFTR trafficking deficient variant, 
present in 90% of CF patients, treated with ivacaftor/lumacaftor 
or ivacaftor/tezacaftor (Jarosz-Griffiths et al., 2020). A general 
assumption is that restoring CFTR channel activity will result 
in the remission of all downstream defects in pro-inflammatory 
and tissue remodeling pathways, however, there is as yet little 
information on the long-term impact of CFTR modulators 
on abnormalities other than transepithelial Cl− secretion (Rubin 
et al., 2019). Ruffin et al. (2018) showed that the inflammatory 
response of primary differentiated CF airway cells to bacterial 
toxins is reduced by ivacaftor/lumacaftor, dependent on the 
rescue of CFTR activity. However, this does not explain 
oxidative stress and enhanced pro-inflammatory signaling in 
CF epithelial cells under basal conditions reported by us 
previously (Stolarczyk and Scholte, 2018; Stolarczyk et  al., 
2018), which may contribute to the development of early CF 
lung disease.
Studies in CF patients show a large variation in lung pathology 
and inflammation parameters, may be  confounded by 
environmental factors, and do not provide detailed information 
about molecular mechanisms or the contributions of different 
cell types involved in CF pathology. Model studies using 
immortalized epithelial cell lines are limited by the poor 
the approved combination therapies, ivacaftor/lumacaftor and ivacaftor/tezacaftor/
elexacaftor, did not effectively suppress the inflammatory phenotype. We propose that 
CFTR deficiency causes oxidative stress in CF airway epithelium, affecting multiple 
bioactive lipid metabolic pathways, which likely play a role in CF lung disease progression. 
A combination of anti-oxidant, anti-inflammatory and CFTR targeted therapeutics may 
be required for full correction of the CF phenotype.
Keywords: cytokine array, cystic fibrosis transmembrane conductance regulator corrector therapy, oxidative 
stress, polyunsaturated (essential) fatty acids, ceramide species, bronchial epithelial cell, lipidomics, 
cystic fibrosis
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differentiation and genetic instability of cell lines, compared 
to human organs in situ and by their lack of individual variation.
We have performed mass spectrometric lipid analysis and 
protein arrays to study lipidomics and inflammatory markers 
in well-differentiated primary airway cells in air-liquid interface 
(ALI) from human patients carrying different CFTR variants 
(CF HBEC-ALI) and newborn CFTR KO pigs (Klymiuk et  al., 
2012; PigBEC-ALI), compared to control. This has enabled us 
to determine lipid and cytokine alterations in CF airway epithelial 
cells and responses to pharmaceutical interventions under well-
controlled conditions in three independent models of CF and 
examine the variation between individual responses in vitro.
MATERIALS AND METHODS
CF Mice and CF Pigs
Breeding of adult (80–115  days) Cftrtm1eur F508del CFTR 
homozygous mice and sex- and age-matched normal littermates 
(F12 C57BL/6 backcross), isolation of lung tissue and lipid 
extraction for mass spec analysis was as previously described 
(Veltman et  al., 2016). All experiments were performed with 
approval (DEC 138-11-09) of the Independent Committee on 
Ethical Use of Experimental Animals, Rotterdam, according 
to national and European Union guidelines. Freshly excised 
lungs from newborn CFTRKO Piglets and non-CF control 
littermates (Klymiuk et  al., 2012) were obtained from the 
Department of Veterinary Medicine, Ludwig Maximilian 
University, Munich, Germany (Klymiuk et  al., 2012) shipped 
on ice, and processed within 24  h, according to local and EU 
ethical guidelines.
Human Material
Non-CF Human airway epithelial cells were obtained from 
macroscopically normal, tumor-free, anonymous bronchial tissue 
obtained from lung cancer patients undergoing resection surgery 
for lung cancer at Erasmus MC Rotterdam, approved by the 
Medical ethical committee of the Erasmus MC (METC 2012-
512; P5, P10, P11, P24, all-male, ex-smokers 58–76  years old). 
All CF primary epithelial cells, five donors aged 12–32  years 
no history of smoking (Table  1) and one non-CF sample or 
(BP954) were obtained from the CF Translational Center, McGill 
University, Montreal, Canada according to a protocol approved 
by the Institutional Ethics Protocol Review Board of McGill 
University (#A08-M70-14B).
Cell Culture
All cell culture experiments were performed at the Erasmus 
MC Cell biology facility. Primary airway cells from newborn 
CFTR KO and control piglets and human lungs were isolated 
and cultured in parallel at ALI on permeable membranes to 
allow differentiation to airway epithelial cells (Methods BEGM) 
as described in Stolarczyk et  al. (2016, 2018). Undifferentiated 
CF and non-CF primary epithelial cells frozen in liquid nitrogen 
were obtained from the CF Translational Center, McGill 
University, Montreal, Canada where they were prepared according 
to a protocol previously described in detail (Matthes et al., 2018). 
Non-CF undifferentiated primary epithelial cells from Erasmus 
MC were obtained stored in liquid nitrogen and cultured using 
essentially the same method (Amatngalim et  al., 2018). In all 
experiments reported here CF and non-CF cells were obtained 
as undifferentiated primary bronchial epithelial cells, expanded 
submerged on collagen-fibronectin coated flasks in KSFM + 
ROCKinhibitor up to passage 3, and subsequently differentiated 
in parallel on 12 mm transwell inserts with 0.4 μl pore polyester 
membrane (Costar) in ALI culture (BEGM, LONZA), as described 
previously (Stolarczyk et  al., 2016, 2018). Human and neonatal 
CFTR KO and WT Pig BEC-ALI cultured for 21  days, used 
in all experiments, showed comparable trans-epithelial resistance 
(range 400–800 Ω•cm2, N = 65, average 550 ± 150 SD Ω•cm2). 
Differentiated epithelial morphology as shown by lateral cadherin 
(ECAD) and tight junction (ZO-1) staining, and 20–30% ciliated 
cells (Tubulin IV) was verified in all experimental groups. 
Markers of secretory cells (MUC5B, MUC5AC, and SCGB3A1) 
were also tested under these conditions on randomly selected 
samples. No obvious differences between CF and non-CF were 
observed by visual inspection (data not shown), representative 
images of non-CF patients, three donors, are shown in the 
Supplement (Supplementary Figure S1).
Treatment of Differentiated Cells
In all experiments reported, the differentiated cells in ALI 
culture were cultured on BEGM without the addition of EGF 
(BEGM minus EGF) for 24  h to achieve a basal state of EGFR 
signaling, previous to intervention or control in BEGM minus 
EGF (Stolarczyk et al., 2016, 2018). After a further 24 h, media 
were collected, an apical wash was performed, and cells were 
harvested for RNA isolation or lipid analysis. Fenretinide 
dissolved in 95% Ethanol was added to the cultures at 
1,000  ×  stock solution to a final concentration of 1.25  μM. 
Reduced Glutathione (GSH, Sigma) was added as a fresh 10 mm 
solution in BEGM-EGF to the apical and basolateral side, the 
apical medium was removed after 20 min. Deferoxamine (DFO) 
solubilized in PBS was added to 100  μM (HBEC-ALI) or 
TABLE 1 | Short circuit current responses to forskolin (ΔIscForsk) for well-differentiated 
primary bronchial epithelial cells used in this study, after treatment with correctors. 
ΔIscForsk (%WT)
Donor Gender (age) VX-809 VX-445 + VX-661
BCF000174 (F508del/F508del) F (26) 16.2 n/a
BCF000554 (F508del/711+1G-T) M (30) 2.2 21.5
BCF000899 (F508del/I507del) M (32) 7.6 n/a
BCF000191 (F508del/F508del) M (21) 6.1 56.1
BCF000584 (F508del/F508del) F (12) 10.2 65.4
Non-CF data were collected from 11 donors HBEC-ALI (P1), and their mean short circuit 
current response to the cAMP agonist forskolin (ΔIscForsk, 48.4 ± 4.5 μA/cm2, 
Mean ± S.E.M) was used to calculate the average CFTR function after the rescue of CF cells 
expressed as % of non-CF (WT). CF HBEC ALI cells (P1, N = 3) were treated with lumacaftor 
(VX-809), 1 μM for 24 h, or elexacaftor (VX-445) plus tezacaftor (VX-661), 3 μM each for 
24 h, followed by treatment with forskolin and ivacaftor (VX770) 300 nM. SEM is 10% or less 
of the average shown in all experiments. n/a: assay not performed for this donor.
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50 μM (Pig BEC-ALI). Lumacaftor/ivacaftor (a.k.a Orkambi™) 
treatment was simulated by adding 2 μM VX-809 and 0.01 μM 
VX-770 (in 0.03% DMSO final concentration) to the cultures 
for 24  h. The triple compound therapy elexacaftor/tezacaftor/
ivacaftor (a.k.a Trikafta™) was simulated by adding 1  μM 
VX-445-1 (MedChemExpress, Monmouth Junction, NJ), 3  μM 
VX-661, and 0.01  μM VX-770 (SelleckChem, Houston, TX; 
in 0.1% DMSO final concentration) for 24 or 72  h in BEGM 
minus EGF. Media were collected at 24, 48, and 72  h, cells 
were collected at 24 and 72 h. Results were compared to vehicle 
control experiments performed on the same day with cells 
from the same plating.
Electrophysiology
Patients vary in their responses to CFTR modulators in vitro 
HBE cells (Matthes et  al., 2018). To examine the impact of 
CFTR deficiency on lipid profiles and cytokines in cells with 
strong and weak drug responses, cells were studied from the 
CF patients used in lipid analysis, three of which are homozygous 
and two heterozygous for F508del-CFTR, after selection based 
on CFTR dependent responses in Ussing chamber experiments 
(Table  1). Well-differentiated monolayers were pretreated for 
24  h at 37°C with vehicle (0.1% DMSO) or under conditions 
designed to mimic the clinically-prescribed combination drugs 
lumacaftor/ivacaftor (1  μM VX809 for 24  h, followed by acute 
treatment with 300 nM VX770 or 50 μM genistein) or ivacaftor/
tezacaftor/elexacaftor (3  μM VX445-1 plus 3  μM VX661 with 
or without 10  nM VX770 for 24  h). Monolayers were mounted 
in modified Ussing chambers and short-circuit current (Isc in 
μA·cm−2) was measured to assay of CFTR function as described 
previously (Matthes et  al., 2018). Transepithelial voltage was 
clamped at 0  mV except for 2  s bipolar pulses to ±1  mV at 
100 s intervals to monitor transepithelial resistance. A basolateral-
to-apical NaCl chloride gradient was imposed to ensure a driving 
force for Cl− secretion: Apical (in mM): 1.2 NaCl, 115 Na-gluconate, 
25 NaHCO3, 1.2 MgCl2, 4 CaCl2, 2.4 KH2PO4, 1.24  K2HPO4, 
10 Glucose; basolateral (in mM): 115 NaCl, 25 NaHCO3, 1.2 
MgCl, 1.2 CaCl2, 2.4 KH2PO4, 1.24  K2HPO4, 10 Glucose. After 
the short-circuit current had stabilized (typically 2–3  min), Fsk 
(10  μM) was added to both sides to raise intracellular cAMP, 
and this was followed by sequential addition of a potentiator 
(50  μM genistein or 300  nM VX-770), the CFTR inhibitor 
CFTRinh-172 (10  μM) and the purinergic agonist ATP (100  μM, 
apical) to stimulate Ca2+-activated Cl− channels as a positive 
control and to confirm cell viability (Matthes et  al., 2016).
Lipid Analysis
Cells were harvested by scraping from the insert membrane 
in 100  μl PBS + cOmplete Mini protease inhibitor and 
PhosSTOP phosphatase inhibitor (Sigma, at the concentrations 
indicated by the manufacturer), and the lipid fraction was 
extracted using 2  vol (chloroform): 1  vol (methanol): 1  mM 
Butylhydroxyanisol (BHA). Tubes were mixed vigorously and 
centrifuged at 4°C for 5  min at 3,000  rpm. The organic 
phase was recovered and evaporated using a Speedvac and 
stored in liquid nitrogen. The extracted lipids were separated 
as previously described (Guilbault et  al., 2008, 2009; Garic 
et  al., 2017, 2020). Malondialdehyde measurement (MDA), 
was performed by the TBARS assay as described previously 
(Guilbault et al., 2009; Garic et al., 2017, 2020). Nitrotyrosine 
and total ceramides were quantified as previously described 
in detail (Guilbault et  al., 2008, 2009; Garic et  al., 2017, 
2020). Total ceramides were measured by ELISA after TLC 
purification, whereas quantification of the specific ceramides 
species were done using mass spectroscopy using the total 
ceramide pool purified on TLC. Mouse lung lipids was collected 
and analyzed by mass spectrometry after extraction as described 
in (Veltman et  al., 2016).
LC-MS/MS was carried out using a QTrap  5500 mass 
spectrometer (AB sciex) coupled to a Dionex UltiMate 3000 
LC-system. The separation column was Kinetex 2.1 × 50  mm 
C18, guarded with a SecurityGuard 4 × 2.0  mm C18 guard 
pre-column (Phenomenex). The mobile phases were MilliQ 
water (A) and methanol (B), both with 0.01% acetic acid, 
with the following gradient: first minute 20% B, increase to 
35% B in 3  min and further increase to 99% B in 15  min 
and 100% B in 17.1. The 100% B was held for 0.9  min, then 
the gradient was decreased back to 20% B in 1  min and 
column was equilibrated at 20% B for another minute. The 
total run time was 20 min. MS was operated under the following 
conditions: the collision gas flow was set to medium, the drying 
temperature was 400°C, the needle voltage was −4,500  V, the 
curtain gas was 30  psi, ion source gas 1 was 40  psi, and the 
ion source gas 2 was 30  psi. Lipid standards were purchased 
from Sigma Aldrich and Avanti Polar Lipids.
Protein Array Analysis
Basal media were collected 24  h after medium change 
(BEGM-EGF), as described and 10 analyzed on a 96×96 
Fluidigm-based protein array (Olink Proteomics, Uppsala, 
Sweden, Array: IMMUNO/ONCOLOGY) which monitors 
92 known markers of inflammation and tissue remodeling 
(Supplementary Table S1). Data are presented as NPX, a 
normalized protein expression value, which is a unit on a 
log 2 scale, allowing quantitative comparison of every marker 
in different samples, i.e., an NPX difference of +1 represents 
a two-fold difference in marker concentration. Note that 
this does not allow a direct comparison of antigen 
concentrations of different markers (Olink data analysis).
Statistical analysis and graph preparation were performed 
with PRISM8 software in compliance with the PRISM8 statistics 
guide, and with standard procedures set by Erasmus MC 
biostatisticians, tests used are specified in the legends.
RESULTS
Oxidative Stress and Abnormal Lipid 
Profile in Human and Pig CF Primary 
Bronchial Cells
Firstly, we  applied lipid analyses to well-differentiated 
primary bronchial epithelial cells from five CF patients 
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having variable corrector responses (Table  1), and five 
non-CF donors (methods) cultured in parallel under identical 
conditions. The oxidative stress and lipid peroxidation 
marker MDA was elevated in all CF patients compared 
to non-CF controls (Figure 1A). Total TLC purified ceramide 
levels were reduced in CF HBEC-ALI (Figure  1B). The 
ω-3-PUFAs DHA (Figure 1C) and related EPA (not shown) 
were strongly reduced whereas the most prevalent ω-6 
PUFA AA was increased (Figure 1D). LCC species CER14:0 
was enhanced (Figure  1E), whereas the VLCC species 
CER24:0 was reduced relative to control (Figure  1F). This 
illustrates an overall increase of LCC over VLCC levels, 
expressed as pmol/nmol lipid phosphate, in CF HBEC-ALI 
across all LCC (CER14:0, CER16:0) and VLCC (CER22:0, 
CER24:0, CER26:0) ceramide species (Figure  2A). The 
apparent exception of the CER20:4 ceramide species which 
carries the AA chain (20:4), may be related to the enhanced 
levels of this PUFA in CF cells (Figure  1D). The ceramide 
precursors sphingosine and dihydroceramide (DH) were 
also reduced in CF HBEC-ALI under all conditions examined 
(Supplementary Figures S2A,B).
To further establish whether lipid abnormalities are an 
inherent property of CF bronchial epithelia independent of 
their origin or culture conditions and species we  analyzed 
the lipid profiles of well-differentiated primary bronchial 
epithelial cells from neonatal CFTR KO pig bronchial cells 
and littermate control (WT). In CF pig BEC-ALI, very similar 
to human CF HBEC-ALI, we observed elevated levels of MDA 
(Figure  3A), reduced total ceramide levels (Figure  3B). LCC 
species (Figure  3D) were increased whereas VLCC species 
were decreased (Figure 3E) in CFTR KO pig as in CF mouse 
lung tissue, resulting in a four-fold increase in the ratio of 
LCC to VLCC (Figure 2B). The ceramide precursors sphingosine 




FIGURE 1 | Oxidative stress, ceramides, and abnormal lipid metabolism in CF human bronchial epithelial cells in ALI culture. CF HBEC-ALI from five different 
donors (Table 1) compared to non-CF (WT, five different donors, see methods), were analyzed as described in methods. Data were merged from three separate 
experiments, comparing each donor in triplicate or quadruplicate in every experiment, data points are shown representing a single membrane (CF N = 40 filters, 
non-CF N = 25 filters). Horizontal bars represent average, error bars ± SD. (A) malondialdehyde (MDA) pmol/nmol fatty acid. (B) Total ceramides in CF HBEC-ALI. 
(C) Docosohexaenoic acid (DHA) levels (% nmol total fatty acids) are strongly reduced in CF HBEC-ALI compared to WT. (D) arachidonic acid (AA) levels (% nmol 
total fatty acids). (E) Long-chain ceramide (CER14:0). (F) Very long-chain ceramide (CER24:0) expressed as pmol/nmol phosphate. Statistical analysis (unpaired 
T-test) was performed with grouped averages (CF vs. Non-CF) for each different donor.
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(Supplementary Figures S2C,D) similar to CF HBEC-ALI 
cells mentioned above (Supplementary Figures S2A,B). Finally, 
the vitamin A analog fenretinide, which has previously been 
shown to correct the LCC/VLCC ratio in immortalized CF 
cell models (Garic et  al., 2017) and CFTR KO mice (Youssef 
et  al., 2020c), partially normalized all lipid levels in KO pigs 
towards those observed in WT pigs. The oxidative stress 
marker MDA (Figure  3A) and total ceramides (Figure  3B) 
in airway cells from CFTR KO pig were reduced and increased, 
respectively, DHA and AA levels were both corrected 
significantly (Figures  3C,D), and abundance of the LCC 
Cer14:0 and VLCC Cer24:0 were largely normalized 
(Figures  3E,F), as were the levels of ceramide precursors 
(Supplementary Figures S2C,D).
Oxidative Stress Markers and Abnormal 
Lipid Profile in CF Mouse Lung
Very similar abnormalities in lipid levels were observed in CF 
mouse lung as in CFTR KO pig and human CF HBEC-ALI. 
Two markers of oxidative stress, MDA and nitrosylated tyrosine 
(N-Tyr) were elevated in adult F508del CFTR mouse lung 
(Figures  4A,B). There was also a marked reduction in the 
major ω-3 PUFA DHA 22:6 and increased levels of the ω-6 
PUFA AA (Figures  4C,D), resulting in a more than 10-fold 
decrease in the DHA/AA ratio. These observations are consistent 
with our previous findings of reduced sphingosine-1-phosphate 
levels, sterile lung inflammation in these homozygous F508del 
CFTR mice (Cftrtm1EUR BL/6; Veltman et  al., 2016). CF mice 
of this strain showed mild intestinal disease and were fed 
normal chow like their normal (WT) littermate controls, therefore 
abnormal lung lipid ratios are unlikely to reflect a diet-related 
bias. The total amount of ceramide species quantified by ELISA 
after TLC purification was reduced in CF mouse lung (Figure 4E), 
and there was a marked increase in the ratio of LCC (Cer16:0) 
to VLCC (Cer26:0; Figure  4F). The complete averaged profile 
of ceramide species confirmed this trend towards very long 
acyl chains in homozygous F508del CFTR mice relative to 
wild type (compare with Figure  2C).
Partial Correction of Lipid Metabolism by 
CFTR Targeted Therapeutics
To examine if CFTR functional correction can normalize lipid 
metabolism we  treated HBEC-ALI cells from an F508del 
homozygous patient (BCF000174) with VX-809 and VX-770 
to mimic the clinically approved combination drug ivacaftor/
lumacaftor (a.k.a Orkambi). These CFTR modulators enhanced 
CFTR activation by forskolin in Ussing chamber and increased 
apical fluid height up to 25% of WT levels, which is considered 




FIGURE 2 | Enhanced long-chain to very long-chain ceramide species ratio 
in CF airway cells and lung tissue. Lipids were extracted and analyzed by 
mass spectrometry, as described in methods merged and averaged data. 
The bars represent the average concentration of individual ceramide species 
expressed as pmol/nmol total lipid phosphate (pmol/nmol P, error bars: 
SEM). (A) Human bronchial epithelial cells in ALI culture (HBEC-ALI) CF 
(BCF000174; N = 12 inserts) compared to WT (N = 12, three donors, four 
filters each), data merged from three independent experiments. Four other CF 
donors (Table 1) give similar results to BCF000174 as shown in (Figures 1E,F). 
FIGURE 2 | (B) Pig bronchial epithelial cells in ALI culture (PIG ALI) on 
membrane inserts cystic fibrosis transmembrane conductance regulator 
(CFTR) KO (N = 6) and WT littermate (N = 9). (C) Total lung of age- and  
sex-matched adult homozygous mutant F508del CFTR (DD; N = 19) or 
control (WT) littermate mouse (N = 15), as described in methods.
(Continued)
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tested and expected to provide significant clinical benefit to 
patients (Table 1). The low response of BCF000554 may reflect 
a gene dose effect since that patient had a splice site mutation 
at one allele (711 +1G-T) and hence would have only about 
half the number of CFTR transcripts compared to F508del 
homozygous cells. I507del causes a folding and trafficking defect 
very similar to F508del, which is consistent with the level of 
correction observed. While useful in acute stimulation, chronic 
exposure to high concentrations of ivacaftor (VX-770). In cell 
culture models, reduces correction of F508del-CFTR by 
lumacaftor (VX-809; Cholon et  al., 2014; Veit et  al., 2014; 
Matthes et  al., 2016). However, inhibition of functional rescue 
by ivacaftor is negligible at clinically-relevant concentrations 
at 1–10 nM (Matthes et al., 2016; Csanady and Torocsik, 2019). 
Treatment with 10  nM ivacaftor and lumacaftor (2  μM) for 
24 h, reduced levels of the oxidative stress marker MDA towards 
normal values in CF HBEC-ALI (Figure  5A). However, total 
ceramide (Figure  5B), DHA and AA levels (Figures  5C,D), 
and LCC ceramide (CER14:0, Figure  5E) were only partially 
corrected. VLCC (CER24:0) was not significantly affected 
(Figure 5F). Non-CF (WT) cell populations (compare Figure 1) 
served as parallel controls; the data range (average  ±  SEM) 
of the parallel controls is indicated by a hatched bar, 
for comparison.
The triple combination treatment ivacaftor/tezacaftor/
elexacaftor which consists of the correctors elexacaftor 
(VX-445) and tezacaftor (VX-661) plus the CFTR activator 
ivacaftor VX-770, is more efficacious than ivacaftor/lumacaftor 
in improving clinical symptoms, and is also effective in 




FIGURE 3 | Oxidative stress and abnormal lipid balance in CFTR KO PIG bronchial cells in air-liquid interface (ALI) culture is partially corrected by Fenretinide. 
(A) malondialdehyde (MDA) pmol/nmol fatty acid. (B) Total ceramides in CF HBEC-ALI. (C) DHA levels and (D) AA levels (% nmol total fatty acids). (E) Long-chain 
ceramide (CER14:0) and (F) Very long-chain ceramide (CER24:0) expressed as pmol/nmol phosphate. All parameters show significant differences when comparing 
CFTR KO (N = 9) to WT (N = 12), and CFTR KO filters treated with fenretinide (N = 6) in parallel experiments (****Padj < 0.001, unpaired ANOVA, Dunnet, using KO 
as reference control). Results are from two CFTR KO and two wildtype newborn pigs cultured in parallel in two separate experiments. Symbols in the figures 
represent data from single filters, average ± SD.
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These clinical findings were confirmed in vitro under our 
Ussing chamber conditions (Table  1). We  next examined 
the effects of ivacaftor/tezacaftor/elexacaftor on the lipid 
profile and increased the treatment period from 24 to 72  h 
in case the process of adaptation and correction of lipid 
levels is slow compared to the rescue of F508del CFTR 
variant protein. We  compared cells from three different 
patients that had been categorized as high, medium, or low 
responders based on their responses to ivacaftor/lumacaftor 
in Ussing chambers (Table 1). Ivacaftor/tezacaftor/elexacaftor 
reduced MDA levels and increased total ceramide abundance 
in CF HBEC-ALI in a donor- and time-dependent manner 
(Figures  6A,B). There was a gradual correction of DHA 
and AA to near-normal levels in all donors (Figures  6C,D). 
By contrast, CER14:0 and CER24:0 (Figures  6E,F), and by 
inference, the LCC/VLCC ratio (not shown) were only 
partially normalized. These results demonstrate that oxidative 
stress and anomalous lipid levels are CFTR dependent and 
can be  at least partially corrected by currently available CF 
therapeutics. We did not observe a clear correlation between 
individual variation in CFTR functional correction in Ussing 
chambers (Table  1) and correction of the lipid imbalance 
in this experimental paradigm.
Anti-oxidant Treatment Corrects Oxidative 
Stress and Lipid Metabolism
To establish whether CF-related oxidative stress contributes 
to abnormal lipid metabolism, the basal medium was 
supplemented with reduced GSH as described previously 
(Stolarczyk et al., 2018). Exogenous GSH caused a substantial 
decrease in the oxidative stress marker MDA in CF HBEC-
ALI, towards normal values (Figure  7A) whereas there was 
no significant effect on non-CF cells (not shown). GSH 
supplementation partially corrected ceramide, DHA and AA 
levels (Figures  7B,C,D) bringing them closer to those in 
non-CF cells. LCC (CER14:0), was also partially corrected 
whereas CER24:0 was not (Figures 7E,F). The certified drug 
and Fe chelating antioxidant DFO had a similar effect in 
both CF pig (not shown) and human CF bronchial epithelial 
cells (Figure  7). These data suggest that lipid imbalance 




FIGURE 4 | Oxidative stress and abnormal lipid levels in F508del CFTR variant mouse lung. Total lungs from adult male and female mice, homozygous for the 
F508del CFTR allele (DD, N = 19) or age- and sex-matched normal littermates (WT, N = 14), were extracted and lipids were analyzed as described, each data point 
represents a single individual. (A) malondialdehyde (pmol/nmol fatty acid). (B) Nitro-tyrosine. (C) DHA. (D) AA. (E) Total ceramide species after TLC purification. 
(F) LCC(Cer16:0)/VLCC(Cer26:0) ratio (compare Figure 2C). CF and WT lungs differed significantly in all parameters (unpaired T-test p < 0.001).
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CFTR-related oxidative stress and can be  corrected by 
anti-oxidant treatment.
Oxidative Stress and Lipid Imbalance are 
Associated With Enhanced  
Pro-Inflammatory Signaling
To study alterations in cytokines and growth factors in 
well-differentiated CF vs. non-CF bronchial epithelial cells, a 
96×96 microfluidics-based protein array focused on markers 
of inflammation and tissue remodeling was used. Secretion of 
41 cytokines and growth factors was detected by analyzing 
the basal medium of CF and non-CF primary epithelial cells 
(Supplementary Table S1). Twelve of these proteins were altered 
significantly in CF compared to non-CF cultures (Table  2). 
In particular, the neutrophil-activating chemokine CXCL5 is 
upregulated whereas the T-cell activator CCL17 is reduced in 
CF HBEC-ALI (Figure  8).
To examine the role of CFTR using a pharmacological 
approach, well-differentiated HBEC-ALI cells were pretreated 
with ivacaftor/lumacaftor or DFO for 24  h. As shown above, 
both treatments partially corrected the oxidative stress and 
lipid imbalance, however, neither agent altered cytokine output 
significantly in CF or non-CF cells (n  =  3 patients, N  =  4 
each, data not shown). Treatment with the more potent corrector 
combination drug elexacaftor/tezacaftor/ivacaftor for 24–72  h, 
caused modest reductions in levels of the growth factor PFG 
and pro-inflammatory cytokine CCL20  in all three patients 
but did not reduce CXCL5, or CXCL11 significantly 
(Supplementary Figure S3).
By contrast, GSH supplementation did reduce the shedding 
of pro-inflammatory and pro-fibrotic factors CCL20, CSF-1, 
and MCP-1, more than 10-fold in CF HBEC-ALI (three donors, 
21 samples, not shown). CXCL5 and several other factors were 




FIGURE 5 | Partial correction of oxidative stress and lipid imbalance in CF HBEC-ALI by ivacaftor/lumacaftor. Treatment of the high responder (Table 1) 
homozygous F508del CFTR BCF174 HBEC ALI with VX-809 (2 μM) and VX-770 10 nM for 24 h (Ork) causes partial correction of lipid imbalance, compared to 
carrier control (Ctr; N = 12). Non-CF (WT) cells are represented by three donors in quadruplicate each (N = 12). (A) malondialdehyde (MDA) pmol/nmol fatty acid. 
(B) Total ceramides in CF HBEC-ALI. (C) DHA levels (% nmol total fatty acids). (D) AA levels (% nmol total fatty acids). (E) Long-chain ceramide (CER14:0). (F) Very 
long-chain ceramide (CER24:0) both expressed as pmol/nmol phosphate. Most relevant comparisons are indicated (unpaired ANOVA, Dunnet, *** p < 0.001, 
untreated CF as control).
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reliably in the presence of the reducing agent GSH. In summary, 
partial correction of the oxidative stress and abnormal lipid 
profile by clinically approved CF drugs had only modest effects 
on pro-inflammatory cytokine production.
DISCUSSION
The present results extend our previous studies of CF infant 
BALF and CF mouse tissues and clarify the relationship between 
CFTR deficiency, oxidative stress, and abnormal lipid levels.
In this study, we  have shown that CFTR deficient mice and 
well-differentiated bronchial epithelial cultures from two different 
species display similar abnormalities and that they vary in their 
responses to clinically approved CF drugs. Several lipids measured 
in this paper are bioactive modulators of lung inflammation 
and tissue remodeling which interact with multiple signaling 
pathways, are likely to have a causal role in CF pathogenesis, 
and are potential therapeutic targets. The vitamin A analog 
fenretinide corrects the high ω-6/ω-3 (AA/DHA) fatty acid 
ratio (Guilbault et al., 2009), the ratios of LCC/VLCC ceramide 
species and mucus production in CFTR KO mouse lung, and 
plasma lipid imbalance in CF patients (Garic et  al., 2017, 
2020; Youssef et  al., 2020c). Fenretinide also normalizes fatty 
acid ratios and reduces lung inflammation in a mouse model 
of allergic asthma (Kanagaratham et  al., 2014; Youssef et  al., 
2020a,b). Amitriptyline, an inhibitor of an acid sphingomyelinase, 
is reported to improve lung function and body weight in CF 
patients (Adams et  al., 2016). In the present study, we  also 




FIGURE 6 | Partial correction of oxidative stress and lipid imbalance in CF HBEC-ALI by elexacaftor/tezacaftor/ivacaftor triple therapy. CF HBEC ALI were treated 
for 24 or 72 h with the triple combination elexacaftor/tezacaftor/ivacaftor (VX-445 + VX-661 + VX-770; Triple) or vehicle alone (Ctr). CF HBEC ALI inserts of three 
donors, defined by their rescue by ivacaftor/lumacaftor and in Ussing chamber experiments Medium responder (BCF000191) low responder (BCF000554, squares) 
and high responder (BCF000584, triangles; Supplementary Table S1). Filters were analyzed in triplicate at every time point, data points (N = 9) represent single 
inserts. Avarage Levels ± SEM are shown after treatment with elexacaftor/tezacaftor/ivacaftor or control vehicle (Ctr) for 24 or 72 h. Treatment of Non-CF HBEC in 
parallel with elexacaftor/tezacaftor/ivacaftor had no detectable effect at either timepoint (WP945, N = 6, not shown). For comparison, gray bars represent 
average ± SEM of parallel Non-CF data obtained in parallel (three donors, N = 12). (A) malondialdehyde (MDA) pmol/nmol fatty acid. (B) Total ceramides. (C) DHA 
levels (% nmol total fatty acids). (D) AA levels (% nmol total fatty acids). (E) Long chain ceramide (CER14:0). (F) Very long chain ceramide (CER24:0) both expressed 
as pmol/nmol phosphate. Most relevant comparisons are indicated (unpaired ANOVA, Dunnet, *Padj < 0.05, **p < 0.01, ***p < 0.001, using parallel carrier treated 
control at 24 and 72 h, respectively, as control).
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ω-6 to ω-3 PUFA (AA/DHA) ratio, and ceramide species (LCC/
VLCC) ratio in total lung extracts in this model. In CFTR 
KO mice with more severe intestinal pathology, we  recently 
observed that the LCC/VLCC ratio and age-dependent lung 
pathology were both corrected by the retinoic acid analog 
fenretinide (Youssef et  al., 2020c). Taken together, the results 
suggest that both CF mouse and infant CF airways lungs 
present with an inherently abnormal pro-inflammatory milieu 
due to elevated oxidative stress and abnormal lipid metabolism 
even before they become infected. The primary source of this 
skewed signaling in the CF lung remains to be  elucidated.
The results indicate there is elevated oxidative stress, an 
abnormal lipid fingerprint, and enhanced pro-inflammatory 
signaling in well-differentiated bronchial epithelial cells isolated 
from the neonatal CFTR KO pigs and from adult CF patients 
undergoing lung transplantation. Overall, the oxidative stress 
markers lipid peroxidation and protein nitrosylation correlated 
with abnormal levels of essential fatty acids and sphingolipids 
and altered ceramide metabolism in three different models 
of CF; F508del CFTR mouse lung, CFTR KO Pig, and CF 
human epithelial cells in culture. The present data further 
show that these abnormalities are associated with enhanced 
basal cytokine and growth factor shedding and changes in 
gene transcription. In previous studies, we  have shown that 
enhanced activity of the EGFR/ADAM17 axis in CF HBEC-
ALI, which controls the shedding of multiple growth factors 
and cytokines, is tightly regulated by extracellular redox 
signaling (Stolarczyk and Scholte, 2018).
Despite the different origins of the human primary cell 
populations, the CF and non-CF lipid data show little variation 
within each group and no overlap between the groups. Moreover, 
CFTRKO PIG airway epithelial cells and CF mouse lung show 
a very similar signature. We  conclude therefore that oxidative 




FIGURE 7 | Partial correction of oxidative stress and lipid imbalance by anti-oxidants in CF HBEC-ALI. Treatment of CF HBEC ALI with extracellular glutathione 
(10 mM GSH, three different donors (BCF000174, N = 15; BCF000554, N = 3; BCF000889. N = 3; N = 21), or deferoxamine (Def, BCF000191 N = 3, BCF000584 
N = 3) for 24 h, compared to carrier treated parallel controls of the same donors (Ctr), causes partial correction towards non-CF untreated values indicated as 
shaded bars representing untreated non-CF average ± SD (five donors analyzed in parallel, Figure 1). (A) malondialdehyde (MDA) pmol/nmol fatty acid. (B) Total 
ceramides. (C) DHA levels (% nmol total fatty acids). (D) AA levels (% nmol total fatty acids). (E) Long-chain ceramide (CER14:0). (F) Very long-chain ceramide 
(CER24:0) both expressed as pmol/nmol phosphate. Most relevant comparisons are indicated (unpaired one-way ANOVA, Dunnet, *p < 0.05, **p < 0.01, 
***p < 0.001).
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tissue remodeling signaling are cell-autonomous features of 
well-differentiated primary CF airway epithelia.
Future quantitative proteome and transcriptome analysis in 
our model can establish which specific pathways and enzymes 
are affected by CFTR deficiency. A preliminary RNAseq analysis 
of BCF000174 compared to two non-CF donors (WP11, WP21) 
cultured and analyzed in parallel confirms the expression of 
all enzymes known to be  involved in ceramide synthesis, 
including ceramide synthase isozymes, PUFA elongases (ELOVL), 
and fatty acid desaturases (FADS), but the data do not readily 
explain the observed lipid imbalance in CF HBEC-ALI (Scholte 
et  al., 2021). Most likely, the changes in ceramide and PUFA 
metabolism are caused, at least in part, by translational and 
posttranslational events such as trafficking and enzyme 
compartmentalization which, could alter metabolic flux and 
steady-state levels of ceramides and PUFAs. Using a pulse 
labeling technique to quantitate sphingolipids, Loberto et  al. 
(2020) recently reported enhanced ceramide and ganglioside 
levels specifically in the apical membrane of CF compared to 
non-CF in primary airway epithelial cells, differentiated 7 days 
at the ALI, associated with a change in relative localization 
of sphingolipid metabolizing enzymes.
Fenretinide Corrects Oxidative Stress and 
Lipid Imbalance in Airway Epithelial Cells
As discussed below, several pharmaceutical interventions with 
different molecular targets were found to normalize CF lipids. 
Oxidative stress, fatty acid, and ceramide metabolism were 
partially corrected by fenretinide in CFTR KO pig primary 
airway cells, extending recent data confirming its involvement 
in ceramide metabolism obtained from CFTR KO mice (Youssef 
et  al., 2020c) and CF model cell lines (Guilbault et  al., 2009; 
Garic et  al., 2017). Fenretinide has anti-inflammatory 
(Kanagaratham et al., 2014; Orienti et al., 2020) and pro-apoptotic 
activities (Anding et  al., 2018). However, its molecular 
mechanisms are complex, involving both retinoic acid receptor 
(RAR)-dependent and -independent pathways. Fenretinide 
modulates lipid turnover, autophagy, apoptosis, and mitochondrial 
function (McIlroy et  al., 2016), which are affected by epithelial 
CFTR deficiency. It is also noteworthy that fenretinide is a 
selective inhibitor of DEGS1, a sphingolipid desaturase involved 
in the production of ceramides from DH (Rahmaniyan et  al., 
2011). The DEGS1 and parallel DEGS2 pathways may be involved 
in controlling LCC/VLCC ratios and have been proposed as 
a sensor of metabolic oxidative stress (Devlin et  al., 2011). 
Total DH was low and the LCC/VLCC ratio was increased 
in bronchial epithelial cells from CF pigs, and both were 
partially corrected by fenretinide consistent with an upregulation 
of DEGS1 activity. This would provide a molecular basis for 
the reduced DH levels and the enhanced LCC/VLCC ratio in 
CF HBEC-ALI, and the effect of fenretinide on this parameter.
TABLE 2 | Shedding of cytokines and growth factors by primary CF epithelial 
cells compared to non-CF. 
% WT SEM P adj q
CXCL5 771 351 <0.000 <0.000
PGF 453 195 <0.000 0.001
HO-1 429 291 0.008 0.019
IL18 429 251 0.003 0.014
Gal-1 416 249 0.005 0.014
ADA 219 64 0.004 0.014
CAIX 215 66 0.007 0.018
CXCL11 214 60 0.004 0.014
CASP-8 213 53 0.002 0.010
TNFRSF21 49 9 <0.000 0.001
CXCL1 49 15 0.012 0.025
CCL17 28 6 <0.000 <0.000
Relative marker concentration in CF HBEC ALI basal medium compared to non-CF, 
expressed as percentage of average non-CF (%WT, ±SEM) was analyzed using 
Fluidigm™ based protein array analysis (Olink 96×96 Oncology/inflammation), 24 h after 
medium change (BEGM-EGF), merged data from a single array. CF HBEC-ALI (five 
donors, 22 samples) compared to non-CF (four donors, 17 samples). Statistical 
analysis by multiple T-test (discovery defined as more than two-fold change and 
p < 0.05; q < 0.05, was determined using the two-stage linear step-up procedure of 
Benjamini, Krieger, and Yekutieli, without assuming consistent SD).
A
B
FIGURE 8 | Basal shedding of cytokines and growth factors by primary CF 
and non-CF airway epithelial cells. Markers of inflammation and tissue 
remodeling were measured by a Fluidigm-based protein array (Olink 96×96 
Oncology/inflammation) in basal medium (BEGM minus EGF), 24 h after the 
medium change. CF HBEC-ALI (five donors, Table 1, 31 samples) compared 
to non-CF (WT) cultured in parallel (four donors, 17 samples). Complete array 
data are summarized in Supplementary Table S1. Data are expressed as 
NPX (−Log2 expression relative to the internal control). (A) CXCL5 (C-X-C 
chemokine ligand 5) involved in neutrophil activation and angiogenesis is on 
average four-fold (two logs) higher in CF media compared to non-CF. 
(B) CCL17 (C-C motif chemokine ligand 17) involved in trafficking and 
maturation of T-cells is four-fold lower in CF HBEC [statistical analysis on total 
merged array data by multiple T-test p < 0.001, q < 0.001 (Supplementary 
Table S2), and nested T-test of donor-specific data (p < 0.02) shown here].
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CF Related Oxidative Stress Drives Lipid 
Imbalance
The molecular mechanism that links CFTR deficiency with 
oxidative stress has not been firmly established. ER stress due 
to defective processing of F508del CFTR can be  excluded as 
it is observed in cells from CFTR knockout pigs and mice 
that are devoid of CFTR. Several studies have invoked abnormal 
GSH homeostasis (Dickerhof et  al., 2017; de Bari et  al., 2018) 
or deficient membrane trafficking and autophagy (Esposito 
et  al., 2016), and mitochondrial dysfunction (Kleme et  al., 
2018) as sources of cellular stress in CF. While all these 
mechanisms may contribute, they do not yet provide a definitive 
explanation for how the dysfunction of an apical chloride 
channel leads to the complex abnormal lipid phenotype 
reported here.
Deferoxamine and GSH supplementation reduced oxidative 
stress in CF HBEC-ALI and partially normalized PUFA, 
sphingosine, and ceramide metabolism, suggesting a causal 
link between CFTR deficiency-related oxidative stress and 
lipid imbalance. These maneuvers have different molecular 
targets. DFO is an approved drug that is used to treat Fe 
overload toxicity in thalassemia and sickle-cell disease. It 
reportedly has anti-oxidant properties and reduces lipid 
peroxidation and cell injury in an acute model of cigarette 
smoke exposure (Yoshida et  al., 2019), and improves tissue 
regeneration (Vlahakos et  al., 2012; Holden and Nair, 2019). 
Interestingly, Fe accumulation associated with lung pathology 
has been observed in CF lung (Ghio et  al., 2013). GSH is 
a well-known antioxidant in the lung (Cantin et  al., 1987) 
that can be  transported by CFTR (Linsdell and Hanrahan, 
1998; Kogan et  al., 2003). Although we  cannot exclude an 
effect of antioxidants on CFTR activity or an antioxidant 
effect of the CFTR modulators in human CF cells, we  did 
not observe a significant effect of these interventions on lipid 
parameters in non-CF cells (data not shown). Therefore, the 
results suggest that epithelial oxidative stress caused by CFTR 
deficiency, likely involving abnormal Fe homeostasis, alters 
lipid metabolism which might be  partially normalized by 
anti-oxidant treatment in vivo (Holden and Nair, 2019).
CFTR Targeted Therapeutics Partially 
Correct Oxidative Stress and Lipid 
Imbalance
Treatments that mimic ivacaftor/lumacaftor and the more potent 
triple combination therapy elexacaftor/tezacaftor/ivacaftor 
significantly reduced lipid peroxidation but did not normalize 
it completely. Ceramide, sphingosine, DH levels, and LCC/
VLCC ratio were only partially corrected to a similar extent 
by both treatments. DHA and AA levels were substantially 
corrected, 72  h after elexacaftor/tezacaftor/ivacaftor treatment. 
The effect of elexacaftor/tezacaftor/ivacaftor was more pronounced 
after 72  h compared to 24  h in all parameters, suggesting a 
relatively slow process of adaptation at the transcriptional and 
or posttranscriptional level following CFTR rescue. This is 
consistent with the involvement of CFTR function in regulating 
oxidative stress and lipid metabolism, considering the significant 
effect of these compounds on F508del CFTR cAMP-induced 
chloride transport function in Ussing chamber experiments 
within 24  h. Using a different approach in submerged 
immortalized epithelial cells overexpressing F508del CFTR 
(CFBE). Liessi et al. (2020) showed recently that CFTR targeted 
therapeutics, including an elexacaftor/tezacaftor/ivacaftor, changes 
ceramide and lysolipid pools.
The slow and incomplete correction of lipids by CFTR 
correctors in CF HBEC-ALI seems contrary to the general 
assumption that rescuing 10–20% of normal CFTR activity 
measured as forskolin-stimulated short circuit current would 
be sufficient to alleviate clinical symptoms, including downstream 
effects on inflammation and tissue remodeling.
Although we  cannot simply extrapolate our in vitro 
observations to the in vivo situation, the inability to correct 
downstream abnormalities may help explain the variable and 
incomplete therapeutic effect of ivacaftor/lumacaftor in patients 
homozygous for F508del CFTR. Future studies using advanced 
3D culture models of CF lung pathology, and in early CF 
patients, should establish whether elexacaftor/tezacaftor/ivacaftor, 
which shows 5–10 fold higher responses compared to ivacaftor/
lumacaftor in some patients (Table  1), is also more effective 
in long term reduction of oxidative stress, lipid imbalance, 
basal and induced inflammation, and tissue remodeling in 
those patients who do not respond well to ivacaftor/lumacaftor.
Persistent Enhanced Basal Cytokine 
Shedding in CF HBEC-ALI
Abnormal lipid metabolism in CF HBEC correlated with 
enhanced shedding of cytokines and growth factors to the 
basal medium (Table  2, Supplementary Table S1). The data 
highlight the enhanced inducible cytokine CXCL5 involved 
in neutrophil recruitment, tissue remodeling and COPD (Chen 
et  al., 2019), and placental growth factor (PGF) which is 
induced in the lung hyperoxia response, involved in macrophage 
polarization and angiogenesis, and exacerbates pulmonary 
fibrosis (Zhao et  al., 2019; Zhang et  al., 2020). Both proteins 
correlated with oxidative stress markers, inflammation, and 
lung CT scores in CF infant BALF (Horati et  al., 2020), 
consistent with a role of these epithelial factors in early CF 
lung disease. Interestingly the T-cell activator CCL17 was 
reduced in CF HBEC media (Figure  8, Table  2), which may 
be  related to the low T-cell count in CF infant BAL (Scholte 
et  al., 2019) and abnormal T-cell maturation in advanced 
CF lung disease (Hayes et  al., 2020).
The antioxidants DFO and GSH partially corrected oxidative 
stress and lipid metabolism but did not significantly correct 
basal CF HBEC cytokine and growth factor profile in the 
HBEC model. The lack of efficacy of antioxidants suggests 
either that the level of correction is insufficient, or that enhanced 
basal cytokine shedding in CF airway cells is independent of 
oxidative stress and abnormal lipid metabolism. Another 
unexpected finding was that the most effective CFTR modulators 
available, which are in clinical use, were also unable to reduce 
basal inflammatory mediator and growth factor release. Further 
studies are needed to establish if this is due to insufficient 
CFTR correction or to epigenetic changes in CF that require 
Veltman et al. Lipid Imbalance in CF Epithelium
Frontiers in Physiology | www.frontiersin.org 14 February  2021 | Volume 12 | Article 619442
more time or different signals to reduce inflammation, as has 
been extensively documented for asthma and COPD. 
Distinguishing these possibilities could lead to another approach 
for correcting CF lung disease that aimed at modulating 
epigenetic programming (Brasier and Boldogh, 2019; Ebenezer 
et  al., 2019; Alashkar Alhamwe et  al., 2020).
In contrast to DFO, extracellular GSH did reduce a subset 
of pro-inflammatory factors by more than 10-fold, including the 
pro-inflammatory cytokines CCL20, CSF-1, and MCP-1 that in 
BALF from CF infants are correlated with oxidative stress and 
lung disease (Horati et  al., 2020). However, not all proteins 
enhanced in CF HBEC-ALI (Table 1) were affected. The explanation 
for distinct effects could lie in the different modes of action of 
DFO and GSH. DFO affects intracellular ROS production by 
sequestering intracellular Fe stores whereas the antioxidant GSH, 
which is extracellular and relatively impermeant, will likely also 
affect extracellular redox potential and exposed redox-sensitive 
signaling receptors. We  have shown previously that GSH 
supplementation reduced the enhanced growth factor (AREG) 
and pro-inflammatory cytokine (IL6R) shedding in CF HBEC-
ALI, by oxidative inactivation of the EGFR/ADAM17 axis in 
CF HBEC-ALI (Stolarczyk et  al., 2016, 2018). Together, this 
suggests that modulation of intracellular and extracellular oxidative 
stress may contribute towards normalization of inflammation and 
tissue remodeling. N-acetylcysteine reduces inflammation and 
fibrosis in a murine model of Duchenne muscular dystrophy 
(mdx-; Burns et al., 2019). However, treatment of CF lung disease 
patients with available anti-oxidants, including NAC and GSH 
has not been successful (Ciofu et  al., 2020), likely due to the 
unfavorable pharmacodynamics of these compounds.
Lipid Ratios Affect Membrane Mediated 
Signaling
Basal levels of the two major ω-3 PUFA DHA and EPA (data 
not shown), followed the same pattern of responses to 
interventions in CF response. DHA and EPA differentially 
modulate membrane fluidity, lipid oxidation, and signal 
transduction (Sherratt and Mason, 2018) and are precursors 
of resolvins, bioactive lipids that control the resolution of 
inflammation. A combination of EPA and DHA can reduce 
induced inflammation in mouse models of asthma (Fussbroich 
et  al., 2020). Treatment of F508del CFTR mice with a diet 
enriched in ω-3 PUFA reduces lung disease (Portal et al., 2018), 
however, a recent Cochrane meta-analysis of five limited trials 
did not indicate that ω-3 PUFA dietary supplementation is 
beneficial for CF patients (Watson and Stackhouse, 2020).
The role of lipid rafts and ceramide platforms in inflammasome 
activity and downstream inflammation and profibrotic pathways 
has been highlighted by several authors (Grassme et  al., 2014; 
Li et  al., 2019). VLCC deficient CERS2KO mice show enhanced 
LPS induced septic shock and EGFR/ADAM17 activity (Ali 
et al., 2015), consistent with our observations. A profound change 
in the lipid content of CF airway cells as we  have demonstrated 
here may affect inflammasome responses under both basal and 
stimulated conditions. The possible effects of LCC/VLCC and 
AA/DHA ratios on inflammasome activity under basal conditions 
and during a challenge by pathogens should therefore be  the 
subject of future studies. Although well-differentiated primary 
cell cultures in vitro have enabled us to focus on cell-autonomous 
phenomena in the epithelium, this approach is not a true 3D 
model of the airways and does not include the submucosal 
glands, immune system, or underlying connective tissue and 
blood vessels that may influence epithelial behavior. To address 
these complexities and establish the kinetics of cellular adaptation 
to CF pathology and pharmaceutical intervention, future studies 
of CF lung pathology should include long-term treatment using 
an advanced 3D culture model of CF airway epithelium.
Summary and Conclusions
We have shown here that CFTR deficiency causes a closely 
similar pattern of oxidative stress and abnormal lipid metabolism 
in CF mouse lung, differentiated CF pig bronchial epithelial 
cells, and human bronchial epithelial cell. The results, therefore, 
establish this abnormality is an inherent property of CFTR 
deficient airway epithelial cells. In view of the incomplete 
correction of lipid balance and enhanced CF HBEC-ALI cytokine 
shedding by available CFTR targeted compounds, additional 
anti-inflammatory therapy may be required to reduce the effects 
of established CF lung disease.
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GLOSSARY
Term Definition
AA Arachidonic acid, ω-6, 20:4(n-6)
BALF Broncho-alveolar lavage fluid
DHA Docosohexaenoic acid, ω-3 [22:6(n-3)]
EPA Eicosapentaenoic acid, ω-3 [20:5 (n-3)]
GSH Glutahione (reduced)
LCC Long carbon side chain (C14-16) ceramides
MDA Malondialdehyde [HOC(H)=CH-CHO]
VLCC Very long carbon chain (C22-26) ceramides
